Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 8Recruiting 3Terminated 2Withdrawn 1Unknown 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 1

Conditions

Pancreatic Neoplasms 54Biliary Tract Neoplasms 23Nasopharyngeal Carcinoma 22Cholangiocarcinoma 22Carcinoma, Non-Small-Cell Lung 22Urinary Bladder Neoplasms 18Breast Neoplasms 18Neoplasm Metastasis 17Lung Neoplasms 14Lymphoma, Large B-Cell, Diffuse 13Colorectal Neoplasms 12Carcinoma, Transitional Cell 12Non-Muscle Invasive Bladder Neoplasms 10Recurrence 8Ovarian Neoplasms 8Triple Negative Breast Neoplasms 7Sarcoma 7Gallbladder Neoplasms 7Neoplasms 6Hodgkin Disease 6Nasopharyngeal Neoplasms 5Bile Duct Neoplasms 5Adenocarcinoma 5Uterine Cervical Neoplasms 4Locally Advanced Pancreatic Cancer 4Endometrial Neoplasms 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Pancreatic Adenocarcinoma 3Osteosarcoma 3Lymphoma 3

Interventions

Gemcitabine 3130-nm albumin-bound paclitaxel 3Cetuximab 2Bevacizumab 2relacorilant 1pembrolizumab 1Pemetrexed 1Paclitaxel 1Oxaliplatin 1Long Interspersed Nucleotide Elements 1Leucovorin 1Fluorouracil 1Cisplatin 1Carboplatin 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Carcinoma, Pancreatic Ductal × Gemcitabine × Clear all
NCT07259317 2026-04-23

Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

Corcept Therapeutics

Phase 2 Recruiting
60 enrolled
Gastrointestinal

Adenocarcinoma, Carcinoma, Pancreatic Ductal

NCT06447662 2026-04-20

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

Pfizer

Phase 1 Recruiting
330 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

NCT06445062 2026-04-01

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Revolution Medicines, Inc.

Phase 1/2 Recruiting
1,130 enrolled
Gastrointestinal

Gastrointestinal Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡